Novo Nordisk Flags Wegovy Pilla Dist

Novo nordisk On Wednesday, it is said that the results of the late stage testing for their obese tablet showed a “significant” weight loss and tolerability according to blockbuster’s injection, as drug manufacturers seek to obtain oral treatment on the market.

Oasis 4 phase 3 test results that the oral semaglutide pill led to an average weight loss by 16.6% after 64 weeks in obese or overweight and at least the weight of the comorbidities, the Danish pharmaceutical firm said.

The shares jumped at 5.4% to 10:23 time in London (5:23 am).

Novo Novo Chief Scientific Director, called “Wegovy Pill”, Martin Holst Lange said CNBC that oral treatment offered patients an important alternative to an existing injection.

“Our task was to show that with the tablet we could get the same efficiency and the same safety and tolerability as injectable. We have done this now,” Lange said.

“This mainly means that we can offer patients the choice between the tablet and the injection, and it will be important for some patients,” he added.

Oral Novo Nordisk treatment relies on the same Semaglutide GLP-1, which underlies the existing obesity and treatment of diabetes, Wegovy and Ozempic. Wegovy has been shown to reduce weight by 15% on average overweight patients or obese and at least one weight -related disease in the previous Novo study.

Currently, the tablet is under consideration with the US nutrition and drugs, submitted in accordance with a new drug application in February. The decision must be made in the fourth quarter of this year.

If this is approved, the company said the pill would be done completely in the US Increasing its investment in the US Against the background of pressure from the Trump administration to strengthen domestic production.

Analysts detach Reuters on Tuesday this competitor Eli LilyCompetitors’ rival, Orforglipron, can be quickly monitored for approval within one or two months within the framework of the “National Priority Voucher Commissioner” FDA-New Initiative on the further purpose of the Trump administration.

Lange said Novo welcomes “good competition” but added that it was concentrated on the results with drugs, including long -term acceptance.

“In this situation, we are considering the data,” Lange said. “Semaglutide as a tablet can offer 17% body weight loss and with a good security and tolerance profile.”

“What we saw from our competitor is just over 12% of weight loss. And again, we cannot make a direct comparison, but at least we can see the stop speed, believing that Semaglutide may also have (more) effective security and tolerance profile.”

In phase 3 Attain-1 trial released on TuesdayEli Lily said Orforglipron led to average weight loss by 12.4% at the highest dose after 72 weeks in adult or overweight, at least one comorbidation.

However, the American drug manufacturer said on Wednesday that his pills were surpassed by Novo first A study of the head to the head Comparing the effectiveness of two medicines in reducing blood sugar in patients with type 2 diabetes.

Both companies experiment with new so -called next -generation drugs, with Novo on Tuesday Promise of designation In its karilinidal analogue of amiline, long-acting-losing treatment is re-action.

Last week, this Danish company announced plans Cut about 9000 roles As part of a broader upset as part of the new CEO Mike Dussdar, who promised to reset the campaign after a period of weaker growth.

“What we are doing now is focusing on our core, which is diabetes and obesity. This will include constant investment in both diabetes and obesity, as well as how we discussed, associated with comorbidities,” Lange said on Wednesday.